Recently our Founder and CEO, Reginald Swift, sat down with the team at Pharma Tech Outlook magazine to discuss the changes happening with the pharma industry and how digital health, particularly virtual clinical trials are mobilizing access of pipeline therapeutics...
Special Populations Life Science
Company Bridging Science, Technology,
And Research to
Create Products For
Effective And Inclusive Outcomes
To truly close the gap of health inequities in therapeutic outcomes, we’re creating and utilizing platforms that propel us to become proactive in our therapeutic quest for science and discovery to treat every patient.
The tech that we’re powered by.
Virtual Clinical Trials
A system in which the patient can participate in clinical research within given approved health conditions from their couch.
Using designed therapies to focus on their overall increased outcomes for better care.
Our Areas of Support
With tools at our disposal, we’re supporting and delivering services for life science companies to overcome their challenges.
Advisory and subject matter expertise to support organizational challenges
Working in regions across the globe, we’ve come to understand specific disease disciplines very well and work hard to support a growing number of organizations on the viability of effective research outcomes.
Ultra Rare Disease
Neglected, Unknown, and Environmental Diseases
Latest News & Articles
Health Data in the COVID-19 Crisis: How racial equity is widening for patients to gain access to treatment.
The coronavirus pandemic has placed extraordinary demands on the healthcare industry and the groups that are interconnected with the healthcare industry. The strain on obtaining adequate resources to establish a baseline of trending symptomatic patients and severity...
In the wake of the current COVID-19 crisis plaguing the world, many life science and health technology organizations are mobilizing ways to assist in containing and managing patient symptoms as well as racing toward a vaccine. While the world is approximately 12-18...